PHG - Philips expands global footprint of Lung Suite for cancer diagnosis treatment

Royal Philips (NYSE:PHG) said its 3D imaging product Philips Lung Suite had been newly installed with its clinical partners in Belgium, France, Israel, and the UK. The product is used for early lung cancer diagnosis and treatment. The company's Lung Suite is a 3D real-time imaging platform that helps with early precision diagnosis and minimally-invasive treatment, and enables doctors to perform biopsy, ablation, marking of lesions, and/or thoracic surgery procedures, allowing patients to be both diagnosed and treated. The company said several healthcare providers had already successfully diagnosed their first patients using its product, which works in combination with the company’s Image Guided Therapy System – Azurion.

For further details see:

Philips expands global footprint of Lung Suite for cancer diagnosis, treatment